XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues (Tables)
 9 Months Ended
Oct. 01, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Product revenues:
Gross product revenues$357,462 $220,401 $1,051,871 $702,865 
Discounts and allowances(94,345)(51,814)(277,294)(161,668)
Net product revenues263,117 168,587 774,577 541,197 
Collaboration revenues:
License revenues49,694 33,205 116,862 113,318 
Collaboration services revenues15,612 29,300 92,391 62,971 
Total collaboration revenues65,306 62,505 209,253 176,289 
Total revenues$328,423 $231,092 $983,830 $717,486 
Net product revenues by product were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
CABOMETYX$259,791 $159,555 $759,000 $522,381 
COMETRIQ3,326 9,032 15,577 18,816 
Net product revenues$263,117 $168,587 $774,577 $541,197 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Ipsen Pharma SAS12 %16 %17 %16 %
Affiliates of McKesson Corporation15 %12 %15 %13 %
Affiliates of CVS Health Corporation16 %14 %15 %15 %
Affiliates of AmerisourceBergen Corporation16 %11 %14 %11 %
Affiliates of Optum Specialty Pharmacy9 %10 %9 %11 %
Takeda Pharmaceutical Company Limited7 %10 %3 %7 %
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
September 30, 2021December 31, 2020
Ipsen Pharma SAS24 %23 %
Affiliates of McKesson Corporation19 %12 %
Affiliates of AmerisourceBergen Corporation16 %11 %
Affiliates of CVS Health Corporation13 %11 %
Takeda Pharmaceutical Company Limited3 %10 %
Schedule of Revenues Disaggregated by Geographic Region
Revenues by geographic region were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
U.S.$266,436 $171,552 $783,583 $549,379 
Europe38,095 36,006 162,822 117,959 
Japan23,892 23,534 37,425 50,148 
Total revenues$328,423 $231,092 $983,830 $717,486 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2020
$9,853 $3,279 $17,404 $30,536 
Provision related to sales made in:
Current period178,083 22,945 74,851 275,879 
Prior periods(22)(225)1,662 1,415 
Payments and customer credits issued(171,416)(18,789)(70,007)(260,212)
Balance at September 30, 2021
$16,498 $7,210 $23,910 $47,618 
Schedule of Other Assets and Other Liabilities Contract liabilities were as follows (in thousands):
September 30, 2021December 31, 2020
Contract liabilities:
Current portion (1)
$7,535 $1,790 
Long-term portion (1)
9,444 3,755 
Total contract liabilities$16,979 $5,545 
____________________
(1)    Presented in Other current liabilities and Long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.